On July 23, 2026, Dyne Therapeutics, Inc. completed an upsized underwritten public offering of 21,045,000 shares of its common stock on the Nasdaq under the symbol DYN. Each share was priced at $20.50, resulting in gross proceeds of about $431.4 million for Dyne. This figure includes 2,745,000 shares from the underwriters exercising their full option to purchase additional shares. The offering, in which all shares were sold by Dyne, aimed to support the clinical-stage company's mission of providing functional improvement for individuals with genetically driven neuromuscular diseases.